受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | NSC 613327 HCl,LY-188011 HCl | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C9H11F2N3O4.HCI |
|||
分子量 | 299.66 | CAS No. | 122111-03-9 | |
Solubility (25°C)* | 体外 | Water | 19 mg/mL (63.4 mM) | |
DMSO | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | ゲムシタビン塩酸塩 (Gemcitabine (LY-188011, NSC 613327) HCl) は DNA 合成阻害剤であり、 PANC1 細胞、 MIAPaCa2 細胞、 BxPC3 細胞および Capan2 細胞における IC50 はそれぞれ 50 nM, 40 nM, 18nM, 12 nM です。 |
---|---|
in vitro | Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48 hours results in a dose-dependent increase in NF-κB binding. In contrast, NF-κB DNA binding is decreased in BxPC-3 cells treated with the higher Gemcitabine doses for 48 h; however, 24-h treatment with these higher doses increases NF-κB binding in BxPC-3 cells [2] |
in vivo | Intratumoral NF-κB activity is significantly elevated (1.3- to 1.8-fold) in the Gemcitabine-treated mice compared to the PBS-treated mice, suggesting that Gemcitabine also induces NF-κB activation. [2] |
特徴 | Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity. |
細胞アッセイ | 細胞株 | BxPC-3, MIA PaCa-2, and PANC-1 cells |
---|---|---|
濃度 | 0.2 μM | |
反応時間 | 24 hours or 48 hours | |
実験の流れ | BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate. After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine for an additional 24 hours or 48 hours. Apoptosis is quantified using the Cell Death Detection ELISA to detect the amount of cytoplasmic histone-associated DNA fragments and expressed relative to vehicle-treated cells. | |
動物実験 | 動物モデル | Athymic nude mice with MIA PaCa-2 cells |
投薬量 | 50 mg/kg or 100 mg/kg | |
投与方法 | Administered via i.p. |
|
Data from [Data independently produced by Nucleic Acids Res, 2014, 42(10), 6436-47]
Data from [Cancer Immunol Immunother, 2013, 62, 383–391]
Data independently produced by , , Dr. Helen Sadik of Johns Hopkins University
UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT [ Int J Biol Sci, 2024, 20(4):1389-1409] | PubMed: 38385072 |
A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer [ Phytomedicine, 2024, 155377] | PubMed: none |
Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells [ Int J Mol Sci, 2024, 25(6)3211] | PubMed: 38542184 |
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma [ Neoplasia, 2024, 47:100951] | PubMed: 38039923 |
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer [ Drug Resist Updat, 2023, 71:101005] | PubMed: 37647746 |
Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation [ Nat Cell Biol, 2023, 25(2):309-322] | PubMed: 36646789 |
Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects [ Nat Commun, 2023, 14(1):3450] | PubMed: 37301933 |
A living ex vivo platform for functional, personalized brain cancer diagnosis [ Cell Rep Med, 2023, S2666-3791(23)00156-8] | PubMed: 37192626 |
Quantifying heterogeneity to drug response in cancer-stroma kinetics [ Proc Natl Acad Sci U S A, 2023, 120(11):e2122352120] | PubMed: 36897966 |
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer [ Cell Death Dis, 2023, 14(4):295] | PubMed: 37120688 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。